AK0529
Phase 3Small molecule
AK0529 is one of 6 small molecule programs targeting RSV Infection. It is currently in Phase 3.
1
Indications
9
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in RSV Infection
#DrugCompanyPhaseTrials
1BEYFORTUS
SanofiPhase 3
ENFLONSIA
Merck & Co.Approved
Rsvpref
PfizerPhase 3
ABRYSVO
PfizerPhase 3
AK0529
SShanghai Ark Biopharmaceutical Co., Ltd.
Phase 3
Zelicapavir
EEnanta Pharmaceuticals, Inc
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Infants2 trials
RSV Infection2 trials
2 more indications
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AK0529. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details